Pubblicazioni

Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives  (2011)

Autori:
DALLA POZZA, Elisa; Donadelli, Massimo; Costanzo, Chiara; Zaniboni, Tatyana; Dando, Ilaria; Franchini, Marta; Arpicco, S; Scarpa, Aldo; Palmieri, Marta

Titolo:
Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives

Anno:
2011

Tipologia prodotto:
Articolo in Rivista

Tipologia ANVUR:
Articolo su rivista

Lingua:
Inglese

Formato:
A Stampa

Referee:

Nome rivista:
Free Radical Biology and Medicine

ISSN Rivista:
0891-5849

N° Volume:
50

Numero o Fascicolo:
8

Intervallo pagine:
926-933

Parole chiave:
pancreatic adenocarcinoma; gemcitabine; zinc; dithiocarbamate; oxidative stress; apoptosis

Breve descrizione dei contenuti:
Pancreatic adenocarcinoma is a common malignancy that remains refractory to all available therapies, including the gold standard drug gemcitabine (GEM). We investigated the effect of the combination between GEM and the ionophore compounds pyrrolidine dithiocarbamate (PDTC) or disulfiram [DSF, 1-(diethylthiocarbamoyldisulfanyl)-N,N-diethyl-methanethioamide] on p53(-/-) pancreatic adenocarcinoma cell growth. PDTC or DSF synergistically inhibited cell proliferation when used in combination with GEM by inducing apoptotic cell death. This effect was associated to an increased mitochondrial O(2)(.-) production and was further enhanced by zinc ions. Basal levels of mitochondrial O(2)(.-) or manganese superoxide dismutase (MnSOD) strictly correlated with the IC(50) for GEM or the percentage of synergism. Thus, the most relevant values of the antiproliferative synergism were obtained in GEM-resistant pancreatic adenocarcinoma cell lines. Interestingly, the GEM-sensitive T3M4 cells transfected with MnSOD expression vector showed mitochondrial O(2)(.-) and IC(50) for GEM similar to those of resistant cell lines. In vivo experiments performed on nude mice xenotransplanted with the GEM-resistant PaCa44 cell line showed that only the combined treatment with GEM and DSF/Zn completely inhibited the growth of the tumoral masses. These results and the consideration that DSF is already used in clinics strongly support GEM and DSF/Zn combination as a new approach to overcome pancreatic cancer resistance to standard chemotherapy.

Pagina Web:
http://preview.ncbi.nlm.nih.gov/pubmed/21236335

Id prodotto:
58831

Handle IRIS:
11562/347594

depositato il:
29 febbraio 2012

ultima modifica:
17 novembre 2022

Citazione bibliografica:
DALLA POZZA, Elisa; Donadelli, Massimo; Costanzo, Chiara; Zaniboni, Tatyana; Dando, Ilaria; Franchini, Marta; Arpicco, S; Scarpa, Aldo; Palmieri, Marta, Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives «Free Radical Biology and Medicine» , vol. 50 , n. 82011pp. 926-933

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

Progetti Collegati
Titolo Dipartimento Responsabili
<<indietro

Attività

Strutture

Condividi